Autoimmune diabetes

November 4, 2019

Curing, preventing, and reversing autoimmune diabetes  (TIDM) with Tellurium Compounds: Ammonium trichloro(dioxoethylene-o,o’)tellurate (AS101), an immunomodulator, increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 4/November/2019, 12.10 pm

Introduction: What they say A study from the International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, “L. Sacco” Department of Biomedical and […]
November 1, 2019

Molecular mechanistic insights into how Teplizumab delays the development of autoimmune diabetes  (TIDM):  Teplizumab (also known as PRV-031/MGA031/hOKT3γ1), a humanized anti-CD3 monoclonal antibody,  increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and delays development of  type I diabetes (TIDM), via up-regulation of its target gene, 1/November/2019, 12.20 pm

Introduction: What they say A study from the International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, “L. Sacco” Department of Biomedical and […]
August 23, 2019

Combinatorial therapy for autoimmune diabetes  (TIDM):   A pharmaceutical mixture encompassing Dulaglutide (trade name: Trulicity), a Glucagon-like peptide-1  (GLP-1) receptor agonist, and Verapamil (brand name: Calanm, Isoptin and others), an anti-hypertensive drug,  increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 23/August/2019, 11.38 pm

Introduction: What they say A study from the International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, “L. Sacco” Department of Biomedical and […]
August 20, 2019

Natural product-based curative therapy for autoimmune diabetes  (TIDM):  Repurposing the anti-malarial drug Artesunate into an anti-diabetic drug:  Artesunate, a derivative of Artimesinin, which aids in the treatment of malaria, increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 20/August/2019, 10.09 pm

Introduction: What they say A study from the International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, “L. Sacco” Department of Biomedical and […]